Sign In

Laura Benjamin

CEO and President at OncXerna

Professional Background

Laura Benjamin is a prominent expert in cancer research and development, known for her unwavering dedication to advancing the field and addressing the critical unmet needs of cancer patients. With over two decades of experience in academic research and pharmaceutical R&D, Laura has established herself as a passionate and thoughtful leader. Her innovative approach to pushing the boundaries of what is possible has equipped her to tackle the complex challenges that arise in cancer treatment and drug development.

In pursuit of her mission to drive change in cancer drug development, Laura took a significant step by founding OncXerna Therapeutics. As the sole founder and the CEO of this Boston-based global precision medicine company, Laura has been instrumental in building a team that includes a significant presence in Shanghai. OncXerna is committed to delivering next-generation precision medicine strategies aimed at meeting the needs of cancer patients who are currently underserved by traditional treatment approaches. Through the effective use of groundbreaking scientific and computational technologies, Laura has positioned OncXerna as a recognized leader in precision medicine.

Prior to her inspiring venture with OncXerna, Laura served as the Vice President of Oncology at Eli Lilly and Company after the merger with ImClone in 2009. In this role, she spearheaded various cancer discovery and translational initiatives at the New York and Indianapolis sites. Her leadership was pivotal in building a highly effective cross-company team that united the talents of both ImClone and Eli Lilly staff. The challenges faced in biomarker-driven clinical development during her tenure further motivated her decision to create OncXerna.

Education and Achievements

Laura Benjamin's academic contributions are equally impressive and form a solid foundation for her successful career in cancer research. She spent 13 impactful years as a faculty member in the Department of Pathology at Harvard Medical School, where her research focused on understanding the cellular and molecular mechanisms driving cancer progression. A significant area of her study was the role of the tumor microenvironment in relation to cancer growth and responsiveness to targeted therapies. Laura also served as the Associate Director of the Center for Vascular Biology at the Beth Israel Deaconess Medical Center, reflecting her deep commitment to advancing scientific understanding in the field.

Throughout her academic career, Laura has been recognized for her exceptional mentoring skills, earning accolades from Harvard Medical School for her dedication to nurturing students, postdoctoral researchers, and junior faculty members.

Laura earned her PhD in Molecular Biology at the University of Pennsylvania in 1995, where she conducted groundbreaking research on a pediatric cancer-driving fusion protein. Her work included developing methodologies to extract and amplify chromosomal fusions from paraffin-embedded tissues, showcasing her early engagement in the field of molecular pathology. Laura also holds a Bachelor of Arts in Biology from Barnard College, Columbia University, which instilled in her a strong foundation in biological sciences.

In addition to her research and educational pursuits, Laura contributed to the scientific community as a senior editor for 'Cancer Research,' the fundamental journal of the American Association for Cancer Research (AACR) for a decade. She played an active role in shaping the discourse within the realm of cancer research, influencing future studies and perspectives.

Leadership and Advocacy

Laura's commitment to fostering an inclusive scientific community is evident through her leadership initiatives. At Eli Lilly, she was a co-founder of the R&D NY-NJ women’s network, emphasizing her passion for advancing opportunities and support for women in science. She continues to advocate for their empowerment and advancement, serving as a mentor to young scientists and professionals seeking to navigate the competitive landscape of cancer research.

Over the years, Laura has become a valued contributor to the cancer research field, demonstrating both an intellectual prowess and a commitment to social responsibility. Her career reflects a harmonious blend of academic rigor, leadership in the pharmaceutical industry, and an unwavering dedication to improving the lives of cancer patients worldwide.

Related Questions

How did Laura Benjamin's early research at Harvard Medical School inform her later work in precision medicine?
In what ways has Laura Benjamin's experience in pharmaceutical R&D shaped the mission of OncXerna Therapeutics?
What innovative strategies has Laura Benjamin employed to enhance cancer drug development at OncXerna Therapeutics?
How does Laura Benjamin advocate for women in science, and what impact has her work had on this community?
What challenges has Laura Benjamin encountered while leading cross-company teams at Eli Lilly during the merger with ImClone?
Laura Benjamin
Add to my network

Location

Greater Boston Area